AA
MOLN

AlphaCentric Advisors’s Molecular Partners MOLN Stock Holding History

AlphaCentric Advisors’s Portfolio MOLN Stock Details MOLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-32,500
Closed -$218K – 195
2022
Q3 		$218K Buy
+32,500
New +$208K 0.22% 98

Other funds holding MOLN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AlphaCentric Advisors's MOLN Position: Q4 2022 in Review

AlphaCentric Advisors sold out of Molecular Partners (MOLN) in Q4 2022, closing a stake of 32,500 shares — an estimated $218K sold.

AlphaCentric Advisors first reported a position in MOLN in Q3 2022 and held it in 1 quarter. The position peaked at $218K in Q3 2022. 8 funds tracked by Wall St. Rank hold MOLN as of Q4 2022.

  • AlphaCentric Advisors reported no remaining Molecular Partners position as of Q4 2022 after selling out during the quarter.
  • AlphaCentric Advisors sold 32,500 Molecular Partners shares in Q4 2022, an estimated $218K.
  • AlphaCentric Advisors first reported a position in Molecular Partners in Q3 2022 and held it in 1 quarter.
  • AlphaCentric Advisors's Molecular Partners position peaked at $218K in Q3 2022.
  • 8 funds tracked by Wall St. Rank held Molecular Partners as of Q4 2022.

Based on AlphaCentric Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.